Efficacy and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, as Add-On to Insulin in Patients With Type 1 Diabetes

In this phase II trial (n=351), more patients had both HbA1c reduction ≥0.4% and no increase in body weight with canagliflozin 100 and 300 mg v placebo at week 18 (36.9%, 41.4%, 14.5%, respectively; P<0.001) in patients receiving insulin for type 1 diabetes.

Canagliflozin (Invokana) is currently only licensed in type 2 diabetes in UK.

 

The study showed an increased incidence of ketone-related adverse effects (AEs) (5.1%, 9.4%, 0%), including the specific AE of diabetic ketoacidosis (4.3%, 6.0%, 0%), with canagliflozin 100 and 300 mg versus placebo.